Aspire Biopharma Holdings Inc (ASBP)

$1.30 -0.13 (-9.09%)
Market Cap 3.84M
Revenue (ttm) 0.00
Net Income (ttm) -12.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.54
Volume 243,800
Avg Vol 1,220,749
Day's Range N/A - N/A
Shares Out 2.69M
Stochastic %K 53%
Beta 0.81
Analysts Strong Buy
Price Target N/A

Company Profile

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testos...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 592 7399
Address:
23150 Fashion Drive, Suite 232, Estero, United States
Arnie_510
Arnie_510 Feb. 23 at 11:08 PM
$ASBP ✔️Hype Hype Hype ✔️Convert Convert Convert ✔️Dilute Dilute Dilute ✔️Reverse Stock Split ✔️Wash Rinse Repeat
0 · Reply
juned
juned Feb. 23 at 8:37 PM
$ASBP The 'Omnibus Patent' filed over the last month proves they aren’t just a one-trick pony. Look at the markets they are de-risking right now: ✅ CNS (Anxiety) Market: Just filed for sublingual Xanax (Alprazolam). Rapid onset is a game-changer for panic attacks. ✅ Nausea/Motion Sickness: New patents for Zofran (Ondansetron) and Dramamine (Meclizine). No water needed, no GI delay. ✅ Cardio Market: Plavix and Instaprin lead the charge. This is a multi-billion dollar safety net. AND THE BIG BOMBS ARE NEXT: 💣 🔹 ED Market: Formulation for rapid-acting Sildenafil/Tadalafil is in the works for H1 2026. Bypassing the stomach means faster results—period. 🔹 Semaglutide (Weight Loss) Market: The holy grail. They are finalizing a needle-free, sublingual GLP-1. If they capture even 1% of the Ozempic/Wegovy crowd, this ticker isn't a penny stock anymore.
0 · Reply
juned
juned Feb. 23 at 8:35 PM
$ASBP ✅ De-Risked Platform: FDA confirmed NO more studies needed for OTASA (Aspirin). We have a clear 505(b)(2) path to NDA in H2 2026. IP strengthened. ✅ Debt Free: The $9.6M legacy debt cliff is GONE. Balance sheet is cleaned. ✅ Nasdaq Compliant: Full compliance regained as of Friday. The delisting ghost is officially busted. 👻 ✅ Big Pharma doesn't partner with penny stocks; they partner with clean, authorized shells ready for 9-figure licensing deals. They need to give shareholders a reason to say yes for the meeting .
0 · Reply
TheMostInterestingMan
TheMostInterestingMan Feb. 23 at 8:21 PM
$ASBP Patent PR on sublingual Viagra / Cialis inbound
1 · Reply
qfcjhn
qfcjhn Feb. 23 at 8:12 PM
$ASBP Novice question: After the filing of an S-1 and then the SEC's declaration of effect, when exactly can the registered shares be resold on the market? What do you think the real short-term impact will be on the free float and selling pressure? Could this morning's decline be related to this regulatory sequence, or is it a coincidence?
1 · Reply
Leo70o
Leo70o Feb. 23 at 8:10 PM
$ASBP Let’s go for that $5 and $10. Don’t let the dip trick you into selling for a loss that’s exactly what they want. Just stay strong and hold
0 · Reply
Dannyfor
Dannyfor Feb. 23 at 7:55 PM
$ASBP bought some more today.
0 · Reply
TheMostInterestingMan
TheMostInterestingMan Feb. 23 at 7:54 PM
$ASBP buying more.
0 · Reply
Strat579
Strat579 Feb. 23 at 7:47 PM
$ASBP Market is down today. When it bounces back up, we will continue our healthy move up. Slow and steady is not sexy, but we’ll get to our $5-10 eventually.
0 · Reply
WorsttradereverBadluck
WorsttradereverBadluck Feb. 23 at 6:23 PM
$ASBP 700m new Shares incoming
0 · Reply
Latest News on ASBP
Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements

Feb 20, 2026, 8:00 AM EST - 3 days ago

Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements

Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record

Feb 19, 2026, 8:00 AM EST - 4 days ago

Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))

Feb 17, 2026, 8:30 AM EST - 6 days ago

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))

Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

Feb 13, 2026, 8:00 AM EST - 10 days ago

Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

Feb 12, 2026, 8:00 AM EST - 11 days ago

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

Feb 11, 2026, 7:45 AM EST - 12 days ago

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 10, 2026, 8:00 AM EST - 13 days ago

Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit

Feb 5, 2026, 8:00 AM EST - 18 days ago

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution

Feb 3, 2026, 8:00 AM EST - 20 days ago

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution

Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

Jan 29, 2026, 8:00 AM EST - 25 days ago

Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks

Jan 27, 2026, 8:00 AM EST - 27 days ago

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

Jan 22, 2026, 8:00 AM EST - 4 weeks ago

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign

Jan 21, 2026, 8:00 AM EST - 4 weeks ago

Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

Jan 20, 2026, 8:00 AM EST - 4 weeks ago

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

Aspire Biopharma Announces Reverse Stock Split

Jan 14, 2026, 8:00 AM EST - 5 weeks ago

Aspire Biopharma Announces Reverse Stock Split

Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

Jan 7, 2026, 8:00 AM EST - 6 weeks ago

Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine

Dec 18, 2025, 8:30 AM EST - 2 months ago

Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Dec 12, 2025, 5:00 PM EST - 2 months ago

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Aspire Biopharma Provides Q3 2025 Business Update

Dec 4, 2025, 9:00 AM EST - 2 months ago

Aspire Biopharma Provides Q3 2025 Business Update

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Dec 2, 2025, 9:00 AM EST - 2 months ago

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

Nov 26, 2025, 9:00 AM EST - 3 months ago

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

Nov 6, 2025, 9:00 AM EST - 3 months ago

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

Oct 6, 2025, 8:30 AM EDT - 5 months ago

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

Oct 3, 2025, 11:30 AM EDT - 5 months ago

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

Crude Oil Down 2%; Aspire Biopharma Shares Spike Higher

Oct 2, 2025, 2:44 PM EDT - 5 months ago

Crude Oil Down 2%; Aspire Biopharma Shares Spike Higher

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

Oct 1, 2025, 8:30 AM EDT - 5 months ago

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

Sep 17, 2025, 8:30 AM EDT - 5 months ago

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement

Sep 16, 2025, 8:30 AM EDT - 5 months ago

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Sep 3, 2025, 8:30 AM EDT - 6 months ago

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aug 18, 2025, 8:30 AM EDT - 6 months ago

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

Aug 14, 2025, 8:00 AM EDT - 6 months ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aug 13, 2025, 9:10 AM EDT - 6 months ago

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

Jul 31, 2025, 8:30 AM EDT - 7 months ago

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Jul 30, 2025, 7:45 PM EDT - 7 months ago

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Jul 22, 2025, 10:45 AM EDT - 7 months ago

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

Jul 9, 2025, 8:30 AM EDT - 8 months ago

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Jun 24, 2025, 8:30 AM EDT - 8 months ago

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

Jun 10, 2025, 8:30 AM EDT - 9 months ago

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

May 28, 2025, 8:30 AM EDT - 9 months ago

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

May 20, 2025, 8:30 AM EDT - 9 months ago

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

May 8, 2025, 8:00 AM EDT - 10 months ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Apr 29, 2025, 8:30 AM EDT - 10 months ago

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

Apr 14, 2025, 8:30 AM EDT - 11 months ago

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

Apr 11, 2025, 8:30 AM EDT - 11 months ago

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Apr 9, 2025, 8:30 AM EDT - 11 months ago

Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

Mar 20, 2025, 8:30 AM EDT - 1 year ago

Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation

Mar 11, 2025, 8:00 AM EDT - 1 year ago

An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

Mar 3, 2025, 7:30 AM EST - 1 year ago

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

Feb 25, 2025, 7:30 AM EST - 1 year ago

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

Arnie_510
Arnie_510 Feb. 23 at 11:08 PM
$ASBP ✔️Hype Hype Hype ✔️Convert Convert Convert ✔️Dilute Dilute Dilute ✔️Reverse Stock Split ✔️Wash Rinse Repeat
0 · Reply
juned
juned Feb. 23 at 8:37 PM
$ASBP The 'Omnibus Patent' filed over the last month proves they aren’t just a one-trick pony. Look at the markets they are de-risking right now: ✅ CNS (Anxiety) Market: Just filed for sublingual Xanax (Alprazolam). Rapid onset is a game-changer for panic attacks. ✅ Nausea/Motion Sickness: New patents for Zofran (Ondansetron) and Dramamine (Meclizine). No water needed, no GI delay. ✅ Cardio Market: Plavix and Instaprin lead the charge. This is a multi-billion dollar safety net. AND THE BIG BOMBS ARE NEXT: 💣 🔹 ED Market: Formulation for rapid-acting Sildenafil/Tadalafil is in the works for H1 2026. Bypassing the stomach means faster results—period. 🔹 Semaglutide (Weight Loss) Market: The holy grail. They are finalizing a needle-free, sublingual GLP-1. If they capture even 1% of the Ozempic/Wegovy crowd, this ticker isn't a penny stock anymore.
0 · Reply
juned
juned Feb. 23 at 8:35 PM
$ASBP ✅ De-Risked Platform: FDA confirmed NO more studies needed for OTASA (Aspirin). We have a clear 505(b)(2) path to NDA in H2 2026. IP strengthened. ✅ Debt Free: The $9.6M legacy debt cliff is GONE. Balance sheet is cleaned. ✅ Nasdaq Compliant: Full compliance regained as of Friday. The delisting ghost is officially busted. 👻 ✅ Big Pharma doesn't partner with penny stocks; they partner with clean, authorized shells ready for 9-figure licensing deals. They need to give shareholders a reason to say yes for the meeting .
0 · Reply
TheMostInterestingMan
TheMostInterestingMan Feb. 23 at 8:21 PM
$ASBP Patent PR on sublingual Viagra / Cialis inbound
1 · Reply
qfcjhn
qfcjhn Feb. 23 at 8:12 PM
$ASBP Novice question: After the filing of an S-1 and then the SEC's declaration of effect, when exactly can the registered shares be resold on the market? What do you think the real short-term impact will be on the free float and selling pressure? Could this morning's decline be related to this regulatory sequence, or is it a coincidence?
1 · Reply
Leo70o
Leo70o Feb. 23 at 8:10 PM
$ASBP Let’s go for that $5 and $10. Don’t let the dip trick you into selling for a loss that’s exactly what they want. Just stay strong and hold
0 · Reply
Dannyfor
Dannyfor Feb. 23 at 7:55 PM
$ASBP bought some more today.
0 · Reply
TheMostInterestingMan
TheMostInterestingMan Feb. 23 at 7:54 PM
$ASBP buying more.
0 · Reply
Strat579
Strat579 Feb. 23 at 7:47 PM
$ASBP Market is down today. When it bounces back up, we will continue our healthy move up. Slow and steady is not sexy, but we’ll get to our $5-10 eventually.
0 · Reply
WorsttradereverBadluck
WorsttradereverBadluck Feb. 23 at 6:23 PM
$ASBP 700m new Shares incoming
0 · Reply
Leo70o
Leo70o Feb. 23 at 6:07 PM
$ASBP
1 · Reply
Leo70o
Leo70o Feb. 23 at 5:58 PM
$ASBP i am staying put. Not selling a single share. The shorts won't get anything from me. I am riding this out till the end
1 · Reply
Timetoflytothemoon
Timetoflytothemoon Feb. 23 at 5:55 PM
$ASBP loaded more why not !!
0 · Reply
todayatatime
todayatatime Feb. 23 at 5:40 PM
$ASBP daaay to day
0 · Reply
todayatatime
todayatatime Feb. 23 at 5:31 PM
$ASBP
0 · Reply
Bert1981z
Bert1981z Feb. 23 at 5:17 PM
$ASBP Sell now and buy back at a 30 percent discount next week. Better still invest in something that isn't a dilution machine.
0 · Reply
Evilalchemist
Evilalchemist Feb. 23 at 5:03 PM
$ASBP my guess is insiders haven’t sold because they are skimming money another way if they sold it would be obvious
0 · Reply
Evilalchemist
Evilalchemist Feb. 23 at 5:02 PM
$ASBP this is a .03 share price pre split meaning the stock is a worse position then it was before split that’s why they are looking 1 for 500
1 · Reply
Evilalchemist
Evilalchemist Feb. 23 at 4:59 PM
$ASBP 5 million float right now so they have already added some in somewhere some way
0 · Reply
Evilalchemist
Evilalchemist Feb. 23 at 4:58 PM
$ASBP won’t be but a couple days and they will dilute again the more it drops the less they will get so my guess is 157 million shares before end of week
0 · Reply
Evilalchemist
Evilalchemist Feb. 23 at 4:55 PM
$ASBP even the borrow rates are still very high Asbp won’t recover because the board doesn’t want it to. Pennys on the dollar man they fucked our eyes out lol
0 · Reply
Evilalchemist
Evilalchemist Feb. 23 at 4:49 PM
$ASBP it is crazy it’s still dropping and a lot of shorts closed their position meaning they bought 70k shares back and it’s still falling. They are just barely holding on we are all about to lose every last cent put into this
0 · Reply